| Trial ID: | L2729 |
| Source ID: | NCT01650129
|
| Associated Drug: |
Biphasic Insulin Aspart 50
|
| Title: |
Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 50|DRUG: biphasic human insulin 50
|
| Outcome Measures: |
Primary: Glycosylated haemoglobin A1c (HbA1c) | Secondary: Occurrence of adverse event(s)|Blood glucose|Incidence of hypoglycaemic episodes|Change from baseline in insulin antibodies|Insulin doses
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
83
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2000-12-13
|
| Completion Date: |
2001-10-18
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-24
|
| Locations: |
Novo Nordisk Investigational Site, Tokyo, 1000005, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01650129
|
